This study, led by the Medicines for Malaria Venture in collaboration with the Ministry of Health Uganda, HEPS and WHO, investigated what components make up the final retail price of 8 antimalarials in Uganda and 5 other essential medicines. Investigations were carried out in 2007 in Kampala, in a rural area with little pharmaceutical supply chain infrastructure, and in an intermediate area. It was found that: the importer, wholesaler and retailer add the main price components, which have a cumulative impact; the mark-ups added at each stage vary greatly between sectors and regions; the supply chain is more complex in rural areas; the manufacturer's selling price often makes only a small contribution to the final price; locally produced products are similar in price to imported ones; retail mark-ups make the greatest contribution to final price; marketing practices and affordability can affect mark-ups; and the overall mark-up varies between 120% and 375% depending on the outlet. Recommendations are made for improving the situation. [See also the previously published report 'Understanding the antimalarials market: Uganda 2007 – An overview of the supply side'].
Published by Medicines for Malaria Venture, Geneva, Switzerland, 2008; 34 pp.